Early 1L treatments for advanced HCC were monotherapy with tyrosine kinase inhibitors (TKIs).1
While these early treatments started the journey toward OS and some supporting measures, advancements in combination therapies are more standard today.
10.7 months2
Monotherapy approved 2007
13.6 months3
Monotherapy approved 2015
5.5 months4*
Monotherapy approved 2007
7.3 months3
Monotherapy approved 2015
*Median PFS not tracked. This number indicates time to tumor progression.
PFS=progression-free survival, defined by the FDA as time from randomization until objective tumor progression or death, whichever occurs first.
N/A
Monotherapy approved 2007
19%3
Monotherapy approved 2015
HEMORRHAGE RISK IN EARLY THERAPIES FOR uHCC
In a study of one monotherapy approved for uHCC in 2007, a 2% increase in Grade 3-4 bleeding vs placebo was observed, requiring discontinuation if bleeding necessitated medical intervention.2
Another monotherapy approved in 2015 showed 4% Grade 3-4 hemorrhagic events.3
Discontinuation rates due to adverse events ranged from 20%-32% in early monotherapy with tyrosine kinase inhibitors.2,3
Stay Connected
Sign up to receive information, company news and updates, or to connect with a member of our team.
REFERENCES: 1. Kang S, Bai X, Chen S, Song Y, Liu L. J Interv Med. 2019;2(2):47-51. 2. NEXAVAR. Prescribing information. Bayer HealthCare Pharmaceuticals Inc.; July 2020. 3. LENVIMA. Prescribing information. Eisai Inc.; November 2022. 4. Llovet JM, Ricci S, Mazzaferro V, et al. N Engl J Med. 2008;359(4):378-390.
